How is AI Being Utilised Across the Healthcare Sector, and What Does the Future Hold?

Dr. Zhao Cai is a Professor in Information Systems and Executive Director of Nottingham China Health Institute at University of Nottingham Ningbo China. His research interests focus on digital supply chain management, platform competition, and digital health. Findings from his research have appeared in leading journals such as MIS Quarterly (MISQ), Journal of Operations Management (JOM), Journal of Academy of Marketing Science (JAMS), Journal of Association for Information Systems (JAIS), and International Journal of Operations and Production Management (IJOPM), among others. Dr. Cai serves as the Managing Editor of Industrial Management & Data Systems (IMDS) and an Associate Editor for Internet Research (IR). Additionally, he has served as a Track Chair for the Pacific Asia Conference on Information Systems (PACIS), a Mini-track Chair of the Americas’ Conference on Information Systems (AMCIS), and an Associate Editor for the International Conference on Information Systems (ICIS) and the European Conference of Information Systems (ECIS).

Dr. Jimmy Yao is an UK-trained cardiologist with over 12 years of experience working in the UK national health service (NHS) and holds specialist registration in cardiology and general internal medicine from the UK General Medical Council (GMC). Prior to returning to Shanghai, he served as a consultant cardiologist and general physician in the UK. Dr. Yao has extensive expertise in managing a wide range of cardiovascular conditions, including hypertension, hypercholesterolemia, angina, ischemic heart disease, myocardial infarction, arrhythmias, syncope, and heart failure. He received advanced training in interventional cardiology at the renowned Liverpool Heart and Chest Hospital, where he performed over 1,000 percutaneous coronary interventions (PCI) and developed a strong proficiency in intravascular coronary imaging and intravascular haemodynamic assessment. Dr. Yao is also certified in echocardiography (TTE) and cardiac CT angiography (CTCA), enabling him to offer safe and precise diagnostic services.

As a member of the Royal College of Physicians (RCP), the British Cardiovascular Society (BCS), the British Cardiovascular Intervention Society (BCIS), and the European Society of Cardiology (ESC), Dr. Yao has contributed significantly to medical education. He has served as a tutor for the Royal College of Physicians and played an active role in training the next generation of healthcare professionals. Dr. Yao has also published numerous articles in international journals and presented at renowned academic conferences globally.

Outside professional life, Dr. Yao enjoys engaging in various sports activities and participating in charitable events.

Dr. Layli Türek is a Head of Medical Affairs at Shanghai Taoying Medical Technology, a company specializing in AI-powered dual-plane dynamic X-ray systems for orthopedic applications. She had published over 40 original research papers in internationally well-known journals. She holds a Ph.D. in Respiratory Immunology from Fudan University and has a strong academic and clinical background from her tenure at Huashan Hospital. With over 8 years of experience in medical research and strategic affairs, she focuses on the integration of intelligent imaging technologies into clinical workflows to improve diagnostic accuracy, rehabilitation, and surgical planning in musculoskeletal care.

Max Kirkby spent 35 years in the Pharma industry. An experienced drug development leader, leading both global cross-function drug development teams, development functions and R&D organisations.

During his development career Max brought to market a number of new medicines across multiple therapy areas. Within oncology he has led teams through approvals with US FDA, EMA, PMDA and NMPA including assets with companion diagnostic registration requirements.

Max has lived and worked in UK, USA, Sweden and China and managed development teams globally and R&D organisations in China and Japan. He is an engaging leader who puts a strong emphasis on high-performing teams, individual development, cross-functional working and good governance to drive successful drug development.

Max has more than 14 years experience living and working in China in both global and local leadership roles and is passionate about the importance of including China and other Asian countries like Japan and S Korea in global development from an early stage. This enables both the diversity of expertise from these important countries to be hanced within the global development strategy as well as ensure their patients can access new treatment options at the same time as those in the US and Europe.